Free weekly newsletter

Get the free weekly executive digest

The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New leadership moves, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Leadership Trends

See who's moving and how much in your market

No credit card required Weekly executive digest

Pathios Therapeutics Limited Appoints Paul G. Higham As Chief Executive Officer and Stuart Hughes, Ph.D. To Transition To Chief Scientific Officer

PRIVATEJul 09, 2024•almost 2 years ago

Position

Chief Executive Officer

Company

Pathios Therapeutics

Paul G. Higham

MiltonBiotechnologyTherapeutics

Description

Pathios Therapeutics Limited announced the appointment of experienced biotechnology industry executive, Paul G. Higham, as Chief Executive Officer (CEO), while the founding CEO, Stuart Hughes, Ph.D., will transition to the role of Chief Scientific Officer (CSO). The company is preparing to enter clinical development with its first-in-class GPR65 antagonist.

Company Information

Company

Pathios Therapeutics

Location

Milton, Oxfordshire, United Kingdom

About

Pathios Therapeutics is an early-stage drug discovery company that was established in 2017 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs. Based in Oxford, UK, the company is founded upon a deep understanding of the biology of tumour-associated macrophages (TAMs). We are currently engaged in a fully-enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility across a broad spectrum of cancers. We are also more broadly interested in the potential to target GPR65 for benefit in a range of other serious diseases.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Pathios Therapeutics's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months